Janus Kinase inhibitors (Jak inhibitors) are new drugs targeting the JAK/STAT pathways and are used in several diseases such as rheumatoid arthritis, inflammatory bowel disease, graft vs. host disease, and hemophagocytic lymphohistiocytosis (61). Here, SOAT1 is linked to glycogen storage disease VI.